CHEK.JK PT Diastika Biotekindo Tbk
- Market cap
- IDR 411B
- P/E
- -
- P/B
- -
- ROE
- 6.6%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is CHEK.JK undervalued?
Graham numberThe Graham number of PT Diastika Biotekindo Tbk cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PT Diastika Biotekindo Tbk fundamental analysis
6 of 22 checks passedROE 0/2
Low return on equity (6.6%), below 10%.
ROA 1/1
Return on assets (5.4%) is above the industry median (1.9%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-8.7%) is below the industry median (2.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (6.2%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book is negative or not available.
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield cannot be calculated.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 23.5%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
PT Diastika Biotekindo Tbk stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PT Diastika Biotekindo Tbk
PT Diastika Biotekindo Tbk engages in the sale of disposable or consumable medical goods and diagnostic equipment in Indonesia. It operates through Clinical Diagnostic Group and Life Science Group segments. The company offers various products for detecting, diagnosing, and monitoring human disease. It also provides life science products that are processed from biological products. In addition, the company engages in general trading, laboratory equipment, research, medicine, …
Full company profilePT Diastika Biotekindo Tbk financial statements
PT Diastika Biotekindo Tbk annual financial statements
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Income Statement | |||
| Revenue | 129B | 155B | 201B |
| Gross Profit | 49.6B | 60.7B | 77.1B |
| Operating Income | 15.3B | 21.5B | 23.2B |
| Net Income | 13.6B | 15.2B | 14.0B |
| EPS | 3.34 | 3.73 | 3.41 |
| Balance Sheet | |||
| Total Assets | 97.5B | 119B | 260B |
| Total Liabilities | 19.2B | 25.6B | 48.4B |
| Shareholders' Equity | 78.3B | 93.2B | 211B |
| Cash & Short-term Investments | 21.2B | 19.0B | 68.8B |
| Cash Flow | |||
| Operating Cash Flow | 19.4B | 13.0B | -43.2B |
| Capital Expenditure | 16.1B | 15.2B | 28.4B |
| Ratios | |||
| ROE | 17.4% | 16.3% | 6.6% |
| ROA | 13.9% | 12.8% | 5.4% |
| Net Profit Margin | 10.5% | 9.8% | 7.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PT Diastika Biotekindo Tbk dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 23.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 3.30B | 0.80 | 23.5% |
| 2024 | - | - | - |
| 2023 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns PT Diastika Biotekindo Tbk
- Insiders 79.03%
- Institutions 0.00%
- Public & others 20.97%
- Shares outstanding 4.11B
- Free float 782M
PT Diastika Biotekindo Tbk company profile
- Company name
- PT Diastika Biotekindo Tbk
- Ticker
- CHEK.JK
- Exchange
- Jakarta Exchange
- Sector
- Healthcare
- Industry
- Medical Distribution
- Employees
- 106
- Fiscal year end
- December
- Address
- Jalan Rawa Gelam V Block L, Jakarta Timur, Indonesia, 13930
- Phone
- 62 21 388 65038
- Website
- diastika.co.id
About PT Diastika Biotekindo Tbk
PT Diastika Biotekindo Tbk engages in the sale of disposable or consumable medical goods and diagnostic equipment in Indonesia. It operates through Clinical Diagnostic Group and Life Science Group segments. The company offers various products for detecting, diagnosing, and monitoring human disease. It also provides life science products that are processed from biological products. In addition, the company engages in general trading, laboratory equipment, research, medicine, export and import, pharmaceutical chemicals, services, electronics, and industrial activities. PT Diastika Biotekindo was founded in 1989 and is headquartered in Jakarta Timur, Indonesia. PT Diastika Biotekindo Tbk is a subsidiary of PT Optel Investama Mulia.
PT Diastika Biotekindo Tbk management
8- Mr. Franciscus Xaverius Yoshua RaintjungPresident Director · born 1979
- Muliyati SHead of Finance
- Ricki BudimanGeneral Manager of Operational
- . TyasLegal Manager
- Randi GuntaraMarketing Manager
- Ms. Marcella AngelinFinance Director & Director · born 1987
- Mr. Jeremiah Warren PiskunovHead of Internal Audit · born 1997
- Muhammad Julyana AgustiarCorporate Secretary